Twelve-month clinical and imaging outcomes of the uncaging coronary DynamX bioadaptor system
Stefan Verheye, Mathias Vrolix, Matteo Montorfano, Carlo Zivelonghi, Francesco Giannini, Francesco Bedogni, Christophe Dubois, Bernard De Bruyne, Ricardo A Costa, Daniel Chamié, José de Ribamar Costa Jr, Dean J Kereiakes, Alexandre A Abizaid, Antonio Colombo, Stefan Verheye, Mathias Vrolix, Matteo Montorfano, Carlo Zivelonghi, Francesco Giannini, Francesco Bedogni, Christophe Dubois, Bernard De Bruyne, Ricardo A Costa, Daniel Chamié, José de Ribamar Costa Jr, Dean J Kereiakes, Alexandre A Abizaid, Antonio Colombo
Abstract
Aims: We aimed to assess the safety and efficacy of the DynamX Novolimus-Eluting Coronary Bioadaptor System, a novel device that initially acts as a second-generation drug-eluting stent, but after six months frees the vessel through uncaging elements.
Methods and results: This multicentre study enrolled 50 patients with single de novo lesions. In-device acute lumen gain was 1.61±0.34 mm, and device and procedure success was 100%. Up to 12 months, two target lesion failures occurred: both were cardiac deaths (day 255 and day 267 post procedure). No definite or probable device thrombosis was observed. Mean late lumen loss was 0.12±0.18 mm in-device and 0.11±0.16 mm in-segment. Per intravascular ultrasound, the mean device area and mean vessel area increased significantly by 5% and 3%, respectively, while the mean lumen area was maintained. Stationary optical coherence tomography in seven patients demonstrated restoration of cyclic pulsatility, with an approximate lumen area variance of 11% between systole and diastole.
Conclusions: The DynamX bioadaptor showed drug-eluting stent-like acute performance and safety and efficacy up to one year. Positive remodelling with an increase of vessel and device area while maintaining the mean lumen area was demonstrated. Long-term follow-up and randomised trials are required to assess the benefit of this device on events beyond one year.
Source: PubMed